| [1] 王连云, 吕杰强, 朱雪琼, 等. XRCC1和XPD多态性基因型与上皮性卵巢癌铂类药物敏感性的关系[J]. 温州医学院学报, 2013, 43(4): 224-227.
[2] Jones MB, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer[J]. Proteomics, 2002, 2(1): 76-84.
[3] Baron AT, Boardman CH, Lafky JM, et al. Soluble epider-mal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(2): 306-318.
[4] Rosenthal AN, Menon U, Jacobs IJ. Screening for ovariancancer[J]. Clin Obstet Gynecol, 2006, 49(3): 433-447.
[5] Cannistra SA. Cancer of the ovary[J]. N Engl J Med, 2004,351(24): 2519-2529.
[6] Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface[J].Science, 1985, 228(4705): 1315-1317.
[7] Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications[J].Curr Pharm Des, 2010, 16(9): 1040-1054.
[8] Oyama T, Rombel IT, Samli KN, et al. Isolation of multiplecell-binding ligands from different phage displayed-peptide libraries[J]. Biosens Bioelectron, 2006, 21(10): 1867-1875.
[9] Takakusagi Y, Takakusagi K, Sugawara F, et al. Use of phage display technology for the determination of the targets for small-molecule therapeutics[J]. Expert Opin Drug Discov,2010, 5(4): 361-389.
[10] Ueberberg S, Schneider S. Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo [J]. Regul Pept, 2010, 160(1-3): 1-8.
[11] Zhang Y, Chen J, Hu Z. Panning and identification of acolon tumor binding peptide from a phage display peptide library[J]. J Biomol Screen, 2007, 12(3): 429-435.
[12] Zhang L, Yin G, Yan D, et al. In vitro screening of ovarian tumor specific peptides from a phage display peptide library [J]. Biotechnol Lett, 2011, 33(9): 1729-1735. |
